As more cases of the new coronavirus, COVID-19, are being confirmed globally and in the U.S., researchers have revealed the incubation period for the virus is estimated to be 5.1 days.

Amazon, the e-commerce giant that continues to increasingly dip its toe into the healthcare space, is reportedly working on a vaccine that could cure the common cold, according to CNBC.

The newly incorporated American Board of Artificial Intelligence in Medicine (ABAIM) is soon to begin credentialing healthcare workers in AI, machine learning and deep learning.

Owkin, a New York City-based AI startup, announced it is now working with the University of Pittsburgh to design and validate advanced machine learning models. Once finalized, the new models are expected to have a significant impact in areas such as clinical research and the development of pharmaceuticals.

Several healthcare industry groups are taking steps to inform their provider members to tackle the spread and risks of the new coronavirus, COVID-19.

Countless studies have explored AI’s impact on healthcare providers and the patients they serve—but what about the financial side of things? Looking purely at the bottom line, is AI a wise investment?

The Healthcare Information and Management Systems Society (HIMSS) has officially canceled its 2020 annual meeting in Orlando, Florida, due to continued concerns over the new coronavirus.

AI could provide radiologists with significant value as an advanced peer review tool, according to new findings published in Academic Radiology.